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Abstract
Background: Characterizing breast cancer progression and aggressiveness relies on 
categorical descriptions of tumor stage and grade. Interpreting these categorical de-
scriptions is challenging because stage convolutes the size and spread of the tumor 
and no consensus exists to define high/low grade tumors.
Methods: We address this challenge of heterogeneity in patient-specific cancer 
samples by adapting and applying several tools originally created for understanding 
heterogeneity and phenotype development in single cells (specifically, single-cell 
topological data analysis and Wanderlust) to create a continuous metric describing 
breast cancer progression using bulk RNA-seq samples from individual patient tu-
mors. We also created a linear regression-based method to predict tumor aggressive-
ness in vivo from bulk RNA-seq data.
Results: We found that breast cancer proceeds along three convergent phenotype 
trajectories: luminal, HER2-enriched, and basal-like. Furthermore, 31 296 genes (for 
luminal cancers), 17 827 genes (for HER2-enriched), and 18 505 genes (for basal-
like) are dynamically differentially expressed during breast cancer progression. 
Across progression trajectories, our results show that expression of genes related 
to ADP-ribosylation decreased as tumors progressed (while PARP1 and PARP2 in-
creased or remained stable), suggesting the potential for a differential response to 
PARP inhibitors based on cancer progression. Additionally, we developed a 132-
gene expression regression equation to predict mitotic index and a 23-gene expres-
sion regression equation to predict growth rate from a single breast cancer biopsy.
Conclusion: Our results suggest that breast cancer dynamically changes during dis-
ease progression, and growth rate of the cancer cells is associated with distinct tran-
scriptional profiles.
K E Y W O R D S
disease dynamics, patient heterogeneity, RNA-seq, systems medicine
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1 |  INTRODUCTION
Treatment for breast cancer results in an average 5-year 
survival of 89.7%, stratified by stage at diagnosis ranging 
from 98.7% (for localized tumors) to 27.0% (for distant tu-
mors).1 Doctors facilitating this fantastic treatment success 
in patients rely on multiple classification metrics to decide 
the specific treatment plan for each patient. These classifi-
cation metrics include tumor staging, grading, and subtype 
identification.2 Breast cancer staging integrates informa-
tion about tumor size and spread (local to the lymph nodes 
and distant to other organs) into one categorical score that 
is related to how long a patient has had a tumor, how fast the 
tumor is growing, and how easily the tumor metastasizes.2 
Despite this convolution of growth time, growth rate, and 
metastatic potential and the relatively few staging catego-
ries, staging has clinical prognostic value.3 In contrast to the 
integrative staging score, breast cancer grading measures a 
single characteristic: proliferation index, commonly mea-
sured by mitotic index counting or Ki67 staining.4-7 Like 
tumor staging, grading is assessed as a categorical classifi-
cation––high grade or low grade—rather than a continuous 
score and also has clinical prognostic value.6 Unlike stag-
ing and grading, subtype classification involves grouping 
tumors based on molecular characteristics. Doctors sub-
type breast cancers for different treatments based on muta-
tions2; estrogen receptor (ER), progesterone receptor, and 
human epidermal growth factor receptor 2 (HER2) protein 
expression status6; and more specific molecular subtyping, 
such as the PAM50 classification that groups tumors based 
on a panel of gene expression (ie, as luminal A, luminal B, 
HER2-enriched, basal-like, or normal-like tumors).8 Such 
classification schemes bring with them a paradox: indi-
vidual tumors have widely varying combinations of driver 
mutations and expression levels of subtype-defining mole-
cules, yet many tumors exhibit what have become known as 
the “hallmarks of cancer”, including evading the immune 
system, restructuring of the tissue microenvironment, in-
creasing glycolysis, and shifting other characteristic met-
abolic processes.9 We hypothesize that such hallmarks 
represent a convergent phenotype for cancer cells where 
multiple mutation landscapes combined with a background 
molecular expression in pre-cancerous cells lead to few 
transcriptional—and thereby functional—phenotypes.
Taking advantage of these increasingly stratified pheno-
types, researchers continue to develop increasingly specific 
targeted therapies, including tamoxifen and aromatase in-
hibitors (for ER positive tumors)10 and Olaparib, a PARP 
inhibitor (for HER2-negative tumors and tumors with germ-
line BRCA mutations).2 Despite these and other advances, 
targeted therapies’ development and application do not 
consider tumor progression (as captured by tumor stage) 
or aggressiveness (as captured by tumor grade). Including 
these factors as considerations in targeted therapies is chal-
lenging because there is no clear understanding of how 
molecular regulation dynamically changes during tumor 
progression or across aggressiveness profiles. Further con-
founding this understanding of dynamic molecular regu-
lation in breast cancer is that gene and protein expression 
levels across patients are highly variable due to differences 
in patient history, time of diagnosis, disease presentation, 
and DNA mutations.
In the past, these sources of variability have been treated 
largely as confounding variables obscuring biological 
function. In contrast to this view, leveraging the biological 
variability across individual cancer patients as a biological 
feature can result in a new understanding of disease pro-
gression and severity. In this study, we use gene expression 
across 1215 patients combined with analytical techniques 
adapted from tools originally developed to explore sin-
gle-cell biological heterogeneity and phenotype develop-
ment to predict a molecular natural history of breast cancer 
progression in different subtypes of breast cancer from 
samples taken from individual patients. We also develop 
a transcriptomic signature of cellular growth rate, use it to 
predict tumor doubling time in individual patients, and in-
vestigate the clinical applicability of growth rate estimation 
in breast cancer patients.
2 |  MATERIALS AND METHODS
2.1 | RNA-seq data acquisition and 
normalization
Two datasets were primarily used in this study: the The Cancer 
Genome Atlas (TCGA) breast cancer (BRCA) study11 and 
The Sweden Cancerome Analysis Network for breast can-
cer (SCAN-B) study.12 For the TCGA BRCA study, tumor 
resection samples were collected from treatment-naïve pa-
tients and frozen “soon after surgery” for later sequencing, as 
described previously,11 see also (https://cance rgeno me.nih.
gov/cance rssel ected /biosp eccri teria). For the SCAN-B study, 
treatment-naïve patients and patients receiving neoadjuvant 
therapy were enrolled prior to surgery.12 At the time of pre-
surgical biopsy, additional study biopsies were taken, placed 
in RNA-later (Ambion) and frozen for later sequencing, as 
described previously.12
Primary BRCA and paired-normal breast RNA-seq 
data were downloaded from the TCGA BRCA project 
(available online at https://portal.gdc.cancer.gov/proje cts/
TCGA-BRCA). For data projection and differential expres-
sion analyses, HT-seq counts were normalized using the 
size factor normalization technique available in DESeq2.13 
For development of growth rate and mitotic index regres-
sion equations, raw FPKM values were normalized by 
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conversion to TPM by dividing each sample by the sum of 
its FPKM values.14
2.2 | Single-cell topological data analysis
Single-cell topological data analysis (sc-TDA) was performed 
on the log-transformed RNA-seq data from TCGA BRCA 
whole-tissue, single patient samples using the python imple-
mentation available on Github (https://github.com/Camar aLab/
scTDA).15 Only the top 250 highest weighted genes from a 
PCA analysis of these log-transformed data were used to deter-
mine the scTDA projection. Following scTDA projection and 
classification, we excluded normal-like tumors from our analy-
sis because of low numbers of patients with this phenotype.
2.3 | Consensus Wanderlust to predict 
a CPS
We developed a consensus Wanderlust algorithm based on the 
Wanderlust algorithm designed to predict time-series behav-
ior from “snap-shot” data describing single cells.16 As input 
data to Wanderlust, we used the coordinates from the PCA-
scTDA-projected BRCA patients (see Figure  1), for each 
predefined progression trajectory. This combination of data 
projection and the Wanderlust algorithm uses a graph-based 
approach to predict a progression trajectory through states (or 
samples) based on a random walk through similar states from 
a designated starting point. For our consensus Wanderlust, we 
iteratively ran the Wanderlust algorithm using each nontu-
mor sample as a starting point. This resulted in m Wanderlust 
scores for each data point, where m is the number of nontumor 
samples. We then took the median Wanderlust score as the 
Cancer Progression Score (CPS) for each sample. Thus, our 
CPS is computed based on the assumption that tumors begin 
with expression profiles similar to those of stromal tissue and 
deviate from that expression profile as a tumor persists in the 
stroma. For our analysis, we used the R implementation of 
Wanderlust available in the “uSort” package.17
2.4 | Differential gene expression analysis
Following development of the CPS, samples were grouped 
into discrete CPS levels of size 0.1 from 0 to 1. In all pro-
gression trajectories, this resulted in imbalanced groups, 
so the 0.0-0.1 group was combined with the 0.1-0.2 group 
and the 0.9-1.0 group was combined with the 0.8-0.9 group. 
Differential expression between stroma and cancer was cal-
culated using the Wald test feature in DESeq2 for each can-
cer PAM50 subtype (Luminal A, luminal B, HER2-enriched, 
and basal-like) with all nontumor tissues acting as the control 
for each subtype (ie, using nonpaired statistics). Dynamic 
differential expression during cancer progression was calcu-
lated using a likelihood ratio test comparing the likelihood 
that gene expression is dependent on CPS to the likelihood 
that gene expression is independent of CPS using the likeli-
hood-ratio test (LRT) feature in DESeq2 for each progression 
trajectory (luminal, HER2-enriched, and basal-like). False 
detection rate was estimated using the Benjamini-Hochberg 
procedure, and genes were denoted as differentially ex-
pressed if the FDR corrected P-value was below .05. This 
level was chosen to limit false positives while also identify-
ing a large number of differentially expressed genes to be 
useful for downstream analysis. No fold-change threshold 
was used to identify differentially expressed genes.
2.5 | GO overrepresentation test
We used the online tool PANTHER version 13.1 (http://www.
panth erdb.org/tools /index.jsp) to identify GO Biological 
Processes overrepresented in gene co-expression modules.18 
We performed a statistical overrepresentation test using de-
fault parameters and metabolic genes measured in the TCGA 
BRCA data and included in the generic human metabolic 
model HMR2.019 as a reference background and “GO biolog-
ical process complete” as the annotation dataset or using all 
human genes as the reference background and “GO biological 
process complete” as the annotation dataset. GO-terms were 
considered overrepresented only if FDR-corrected P-values 
were below <.05. Only overrepresented, not underrepre-
sented, GO terms were considered in our analysis.
2.6 | Development of the growth rate and 
mitotic index regression equations
We first obtained previously published RNA-seq data and spe-
cific doubling times from 38 cell lines included in the NCI60 
cell line panel (available online at https://data.broad insti tute.
org/ccle/).20,21 We next converted the RNA-seq data to TPM 
(from FPKM) by dividing reads from each sample by the 
total number of reads in that sample and multiplying by 106. 
We removed genes from the analysis that were not expressed 
in at least 38 out of 42 total samples. We then found genes 
whose log-transformed expression levels correlated with log-
transformed growth rate (absolute value of Pearson correlation 
≥0.64), resulting in 23 genes highly correlated with growth 
rate. We used standard linear regression to develop an equa-
tion relating the log-transformed expression level of these 23 
genes with log-transformed growth rate (see Table S3). This 
method is based on the approach taken by Diener et al.21
We predicted fraction of cells actively proliferating (ie, 
mitotic index) by calculating the PCNA meta-gene score 
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in each of the 405 breast cancer samples available in the 
SCANB cohort of patients (GEO accession: GSE96058) that 
had associated Ki67 quantification.22-24 Linear regression 
was then used to associate Ki67-based mitotic index with 
log-transformed PCNA metagene expression (see Tables S4 
and S5). The predicted growth rates were then corrected for 
fraction of cells actively proliferating as shown below.
where μ is the specific cellular growth rate (measured in 1/h), 
the cellular doubling time is equivalent to the cellular maxi-
mum proliferative doubling time, and the tumor doubling time 
is the time required for the tumor burden to double.25
2.7 | Statistical analysis of growth rate and 
mitotic index predictions
We calculated an r2 value adjusted for number of parameters 
included in the RNA-growth rate regression model to esti-
mate how well our growth rate equation matched measured 
growth rates for our training data using the lm function in 
R.26 For our test data, we calculated how well our RNA-
estimated growth rate matched experimental values for our 
test data using Pearson correlation between calculated and 
measured values. We again used the lm function to estimate 
the correlation between the PCNA metagene expression and 
Ki67 values for the Ki67 index predicting equation (again 
adjusted for number of model parameters).
2.8 | Survival analysis
Cancer predicted growth rate and CPS was subjected to 
standard Cox proportional hazards regression model and 
Kaplan-Meier survival analyses using the “survival” package 
in R with default options, which uses a log-rank test to cal-
culate a P-value comparing survival curves in Kaplan-Meier 
survival analyses.26-28
2.9 | SCAN-B data processing
An additional ~3700 patient samples were included from the 
SCANB dataset.12 Because this dataset is missing many genes 
included in the BRCA TCGA data, we predicted growth rate 
and CPS in the SCANB samples based on gene expression cor-
relation with TCGA BRCA data. Briefly, growth rate was pre-
dicted by correlating growth-associated genes (absolute Pearson 
correlation value ≥0.6 between gene expression and TCGA 
growth rate) between each SCANB sample and all TCGA 
BRCA samples. The growth rate of the TCGA sample with 
the highest correlation was assigned to that SCANB sample. 
A similar procedure was followed for predicting the SCANB 
CPSs, using CPS-dependent differentially expressed genes 
within each PAM50 subtype with the following exception. 
For HER2-enriched cancers, the small samples size in TCGA 
BRCA led to the detection of few genes differentially expressed 
with cancer progression. Therefore, we intersected the differen-
tially expressed genes in common from both luminal and basal-
like cancer, resulting in 16 552 genes differentially expressed 
in both tumor types. We included these genes in the correlation 
analysis for HER2-e tumors from the SCANB dataset. Not all 
of the genes identified from the TCGA dataset-matched genes 
measured in the SCANB dataset (resulting in a 14 254 gene 
overlapped for luminal tumors, a 8440 gene overlap for HER2-e 
tumors, and a 8361 gene overlap for basal-like tumors used for 
the correlation-based analysis).
2.10 | Software availability
The computer code necessary to reproduce the results of this 
study are available as supplemental files. Additionally, an 
R implementation of the regression equations for estimat-
ing growth rate (described above) and all code necessary to 
reproduce the results of this study, including text files con-
taining the genes used in the regression equations and their 
coefficients, are available on Github (https://github.com/
SysBi oChal mers/Cance r-progr ession).
2.11 | Data and materials availability
Data used in this study are available from TCGA (project: 
BRCA) and on the Gene Expression Omnibus website (GEO 
accession: GSE96058).
3 |  RESULTS
3.1 | Developing a pseudo-time series 
of RNA expression during breast cancer 
progression
Because of our hypothesis of a convergent transcriptional 
phenotype for cancer cells despite multiple mutation profiles, 
we used transcriptional data without any associated mutation 
data to explore breast cancer progression and aggressiveness. 
(1)휇corrected=휇uncorrected×proliferation fraction
(2)Cellular doubling time= ln (2)
휇corrected
(3)Tumor doubling time= cellular doubling time
proliferation fraction
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For the purpose of this study, we define progression as how 
a single tumor progresses from a small number of neoplastic 
cells in the primary tumor site to an increasing number of neo-
plastic cells in the primary tumor site that can begin to spread 
throughout the body. Our definition of progression refers only 
to natural progression in the absence of clinical intervention 
does not relate directly to recurrence, effectiveness of treat-
ments, or clinical outcome. We downloaded and normalized 
RNA-seq data for 1215 breast cancers and matched nontu-
morous breast tissue from the breast cancer (BRCA) project 
in The Cancer Genome Atlas (TCGA).11 We used a princi-
pal component analysis and single-cell topological density 
analysis (PCA/scTDA) double projection technique to reduce 
the effects of noninformative gene expression in the data on 
subsequent analyses and to project the RNA-seq data for each 
patient into a lower-dimensional Euclidean space, where each 
point represents the transcriptome of a single sample and the 
distance between two points is related to the similarity of their 
transcriptomes (Figure  1A).15 This double projection tech-
nique showed separation between the coordinated gene ex-
pression of BRCA tumor and nontumorous breast samples; 
the organization of transcriptional phenotypes within BRCA 
tumor samples, however, remained unclear. We, therefore, an-
notated patient samples based on their PAM50 subtype clas-
sification (Figure 1B).8,29 This classification scheme showed 
that the first scTDA axis separated patient tumors based on 
PAM50 subtype. This is not surprising, as gene expression 
was used as the basis for developing the PAM50 classification 
scheme. Based on the separation in scTDA-space, we used a 
three-subtype classification in our subsequent analyses: lumi-
nal, HER2-enriched, and basal-like.
The second scTDA axis appeared to separate patients based 
on their dissimilarity from nontumorous tissue. In addition, this 
dissimilarity is unidirectional: nontumor samples appear at the 
top of the plot, while tumor samples are projected predominantly 
below healthy samples, as opposed to other possible organiza-
tions like radiating outwards. We propose that this axis captures 
broadly the coordinated gene expression changes that occur as a 
cancer progresses from early incidence of tumor formation to a 
more advanced tumor, which is supported by the unidirectional 
projection indicating that one factor is driving this differentia-
tion from healthy tissue in all tumor samples. The assumption 
underlying this proposal is that tumors begin with gene expres-
sion profiles similar to stromal tissue and continue to differ-
entiate their gene expression in a consistent way across tumor 
subtypes as they persist in the stoma. To formalize this proposal 
and more precisely characterize breast cancer progression, we 
developed a modified version of the Wanderlust algorithm 
to construct a pseudo-time series of primary tumor progres-
sion based on RNA-seq data from clinical patients. Briefly, 
the Wanderlust algorithm is a graph-based approach to order-
ing samples along a progression or developmental trajectory 
based on a random walk along an ensemble of nearest-neighbor 
graphs, originally developed for single cells.16 Our modifica-
tion applies Wanderlust multiple times using each nontumor 
sample as a starting point for the algorithm and averages each 
point's Wanderlust score across all applications to calculate a 
CPS. This CPS represents the progression of the primary tumor 
in the absence of treatment. In other words, we use the treat-
ment-naïve samples collected at different points in primary 
breast cancer's natural history (when the cancer was caught in 
individual patients) to construct a “pseudo-natural history” of 
breast cancer, which is represented by the CPS. We applied our 
consensus Wanderlust on each of the three progression subtypes 
(or trajectories) individually (Figure 1C-E) and developed a da-
ta-driven, complete disease progression landscape for primary 
breast cancer (Figure 1F). We then tested how our CPS related 
to discrete cancer staging and found that CPS tended to increase 
with increasing cancer stage (Figure 1G and Figure S1). There 
appeared to be a nonmonotonic relationship between CPS and 
cancer stage: CPS generally seemed to increase with increasing 
stage within stage I and II cancers and within stage III and IV 
cancers (Figure S1); however, CPS seemed to decrease when 
progressing from stage II to stage III tumors. This variability 
could be caused in part by the multiple factors contributing to 
cancer staging: both tumor size and spread, whereas the CPS 
only captures the residence time of a tumor within a stromal 
environment. Whether this is the only factor contributing to the 
nonmonotonic relationship or not, we emphasize that our CPS 
is a data-driven starting point to predict dynamic changes that 
could be occurring during breast cancer progression. Further 
longitudinal studies are required to explore any potential dy-
namic changes occurring in breast cancer that we predict as a 
result of our CPS.
3.2 | Predicting differential gene expression 
during cancer progression
Having developed a CPS, we next investigated how gene ex-
pression changed over the predicted course of breast cancer 
progression. Differential gene expression between tumor and 
stroma has been comprehensively studied elsewhere, including 
analyses using the same dataset as this work.11 Our analysis 
largely captured the same features of breast cancer previously 
described, including increased expression of genes related to 
DNA replication, WNT signaling, and response to unfolded 
protein and decreased expression of genes related to fatty 
acid oxidation, cytokine and chemokine production, response 
to ethanol, and—in luminal B tumors––response to ketones 
(Figure S2).
After the previous standard differential expression analysis 
between tumor and stroma, we next focused on investigating 
how gene expression dynamically changes during breast can-
cer progression. Lumping patients with similar CPS values into 
“progression time steps” allowed us to use standard dynamic 
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differential expression techniques to find genes whose expres-
sion changed during cancer progression; specifically, we used the 
LRT in DESeq2.13 We found that a large number of genes showed 
dynamic differential expression during cancer progression: 
31 296 genes for Luminal tumors, 17 827 for HER2-enriched tu-
mors, and 18 505 genes for Basal-like tumors (see Data S1).
F I G U R E  1  Mapping BRCA treatment-free progression. A, Double PCA/scTDA projection of breast cancer and pair-matched nontumor 
breast RNA-seq data showed gene expression separated nontumor from tumor samples. Tumor samples further separated into three groups. Each 
sample was represented by one point. B, ScTDA axis 1 separated tumors based on PAM50 classification. ScTDA axis 2 appeared to separate 
tumors based on similarity to nontumor tissue, suggesting that scTDA2 may capture cancer progression. C-E, CPS for each progression trajectory 
estimated using consensus Wanderlust. F, Composite CPS for all progression trajectories. G, Relationship between cancer stage and CPS for 
basal-like breast cancer. CPS tended to increase with increasing cancer stage. CPS, Cancer Progression Score; PCA/scTDA, principal component 
analysis/single-cell topological density analysis
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Given the large number of genes dynamically differentially 
expressed, we were especially interested in investigating how 
gene expression of genes related to metabolic function dynam-
ically changed in tumors during predicted breast cancer pro-
gression, an approach made possible by our calculated CPS. 
We found that differential gene expression of metabolism-re-
lated genes during cancer progression was dominated by rel-
atively few co-expression modules (Figure 2). The computer 
code required to reproduce our results is available on Github 
(https://github.com/SysBi oChal mers/Cance r-progr ession) 
and as a supplement to this study (using the Supplemental 
file Predict-Progression-BRCA.R, which calls: Predict-
Growth-Rates.R, Predict-Mitotic-Index.R, ki67_pred_lm.txt, 
nci60_growthRegressionCoeff_updated.txt, and venet_2011_
PcnaGenes.txt). Additionally, an online tool allowing for 
more detailed exploration of these data is available at https://
cookd.shiny apps.io/Cancer_progr essio n/. More differentially 
expressed genes and more nuanced expression patterns were 
found in the luminal trajectory because this trajectory had 
more patient data and a more balanced distribution of CPS, 
leading to a more powerful statistical analysis. As breast can-
cer progresses, all subtypes showed increasing expression of 
genes related to cell cycle, DNA replication and mitochondrial 
function; they also showed decreasing expression of genes re-
lated to angiogenesis, extracellular matrix organization, and 
inflammation (Figure  2). In addition, all subtypes showed 
decreased expression of genes related to ADP ribosylation 
(Figure 2), which may influence the efficacy of PARP inhib-
itors among patients with more progressed tumors; although 
expression of the primary targets of PARP inhibitors (PARP1 
and PARP2) either remained level or increased in expression 
during cancer progression. In HER2-enriched and basal-like 
tumors, progression was associated with a decreased expres-
sion of genes related to retinol metabolic processes. This anal-
ysis highlights cancer as a dynamic disease that restructures 
its microenvironment and dynamically responds to changes in 
the underlying tissue and immune system. Furthermore, our 
results support the idea that, early in cancer progression, can-
cers express higher levels of transcripts related to angiogene-
sis and restructuring the tissue microenvironment than at later 
stages, suggesting that anti-angiogenesis-based treatments 
will likely be more effective during the early stages of breast 
cancer development than at later stages.
3.3 | Predicting cancer growth rates 
across multiple cancer types using an RNA-
based signature
Next, we attempted to use gene expression to predict tumor 
growth rates (and thereby doubling times). We used in vitro 
RNA-seq data from the NCI60 panel of cell lines to develop 
a regression equation predicting cell growth rate from the 
expression levels of 23 genes, using 42 cell lines from the 
NCI-60 panel with high-quality transcriptomics matched to 
growth rates in the same cultures.20,21 We randomly selected 
38 out of 42 of the cell lines as training cells and were able 
to predict growth rate accurately in the remaining test cells 
(Figure 3A). When we tested the growth rate equation in the 
TCGA BRCA data; however, the absolute growth rates pre-
dicted were much higher than observed pathologically. For 
example, the median predicted tumor volume doubling time 
was approximately 2.4  days across TCGA BRCA dataset, 
which is much faster than even the fastest observations of 
tumor volume doubling time (median of 14.5 days for breast 
cancer).30
This led us to a long-standing question in the field of tumor 
biology: what can explain the discrepancy between high in 
vitro growth rates and slow in vivo tumor doubling times.21,31 
Recently, researchers addressed this discrepancy in human pa-
tients using BrdU incorporation to calculate maximum prolifer-
ation doubling time of prostate cancer cells and comparing this 
maximum cellular doubling time to the tumor doubling time, 
measured by prostate-specific antigen levels in the blood.25 
Their data show that maximum cellular doubling time is an 
order of magnitude faster than tumor doubling time. The authors 
speculate that a high rate of tumor cell death may contribute to 
this timing mismatch. In contrast to this explanation, we pro-
pose that this timing mismatch is caused by only a fraction of 
tumor cells replicating at any given time, a well-known feature 
of cancer. In this case, the maximum cellular doubling time is 
only achieved by a fraction of tumor cells. We found that in-
corporating the fraction of proliferating cells (as measured by 
BrdU incorporation) with the maximum cellular doubling time 
led to a prediction of tumor doubling time that matched experi-
mentally observed doubling times closely in this prostate cancer 
dataset (Table S1).
Our regression equation calculates the growth rate of 
cells assuming that all cells from the sequenced population 
contribute equally to gene expression levels. Furthermore, 
because the regression was derived from cells in vitro, it as-
sumes that all cells are growing at equal rates. We therefore 
introduced an additional parameter in our regression model 
corresponding to the fraction of cells in a tumor actively pro-
liferating at any given time (in practice measured by Ki67 
staining, BrdU incorporation, or mitotic index counting). 
The BRCA TCGA data, however, does not include a mea-
sure of fractional proliferation. We therefore derived a gene 
expression-based equation that uses a previously identified 
“PCNA metagene” to predict fractional proliferation, using 
the SCANB breast cancer transcriptomic study for calibration 
(Figure 3B).12,22-24
We then tested how well our gene expression-based regres-
sion equations predicted mitotic index and experimental growth 
rates across breast cancer subtypes in the TCGA BRCA data-
set (Figure  3C,D). We predicted mitotic indexes and growth 
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F I G U R E  2  GO Term overrepresentation analysis of dynamically differential gene expression profiles of breast cancer for each progression 
trajectory using PANTHER.18 Overrepresented GO terms were found using metabolic genes measured in the TCGA BRCA data and included in 
the generic human metabolic model HMR2.019 as a reference background and “GO biological process complete” as the annotation dataset. Terms 
written in grey were found using all human genes as the reference background and “GO biological process complete” as the annotation dataset
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rates that increase with increasingly severe clinical subtypes 
(normal-like, luminal A, luminal B, HER2-enriched, then bas-
al-like) compared to experimentally measured specific growth 
rates.32 These results were not specific to the TCGA BRCA 
dataset; the SCANB dataset showed the same trend, with an 
even greater agreement between predicted and experimental 
specific growth rates across tumor subtypes (Figure 3E,F). We 
also tested our regression equations across seven cancer types 
from TCGA, with some agreement between predicted and ex-
perimentally observed tumor volume doubling time for six can-
cer types (Table S2).
3.4 | Combining predicted disease 
severity and growth rate to predict survival
We investigated if CPS or our growth rate prediction could 
predict overall patient survival in TCGA’s BRCA dataset. 
Specifically, we tested the association of survival with CPS 
and predicted growth using a Cox proportional hazards re-
gression model. We found that the null hypothesis of lack of 
association could not be rejected at the 0.05 level for either 
predictor, and thus we found no evidence for association in 
this data set (P = .059 for CPS and P = .84 predicted growth). 
F I G U R E  3  Predicting growth rates 
from RNA-seq data. A, We used data from 
the NCI60 cell line panel to develop a 
linear regression equation to predict tumor 
growth rates from RNA-seq data. B, We 
next used data from the SCANB breast 
cancer transcriptomic study to relate PCNA 
metagene expression to mitotic index (or 
Ki76 staining). These regression equations 
allowed us to predict (C) mitotic index 
and (D) specific growth rates from TCGA 
BRCA dataset and (E) mitotic index and 
(F) specific growth rates from the SCANB 
breast cancer dataset
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We then tested a larger dataset consisting of ~3700 breast 
tumor samples. We found a possible association between pre-
dicted growth rate and survival (P = .011) and no evidence 
for association between CPS and survival (P  =  .11) when 
considering all PAM50 subtypes together. When considering 
each progression trajectory individually (ie, Luminal, HER2, 
or Basal), this association was not significant at the 0.05 level.
Because chemotherapy is thought to be most effective 
for fast-growing tumors and because it is often a first-line 
treatment for Basal-like breast cancer, we tested whether 
predicted growth rate was associated with survival in che-
motherapy-treated patients with Basal-like breast cancer. A 
univariate analysis indicated that growth rate could be asso-
ciated with survival when stratifying by median growth rate 
(Figure S3). A multivariate analysis using a Cox proportional 
hazards regression model, however, failed to confirm this as-
sociation at a 0.05 confidence level.
4 |  DISCUSSION
This work takes steps to investigates an often-overlooked 
aspect of breast cancer biology: primary breast cancer is a 
dynamic disease. Breast cancer dynamics are widely recog-
nized when related to vascularization (early on in tumor de-
velopment), tumor growth (during tumor development), and 
eventually metastasis (late in breast cancer's natural history). 
Expanding this view of dynamic events related to tumor pro-
gression, our work showed that gene expression in primary 
breast cancer appears to change dynamically throughout the 
natural history of breast cancer. We found an unexpectedly 
large number of genes differentially expressed during breast 
cancer progression across subtypes: in luminal tumors, 55% 
of measured transcripts were dynamically differentially ex-
pressed during progression (31 296 out of 56 830 transcripts 
measured by TCGA consortium); in HER2-enriched tumors, 
31% were dynamically differentially expressed (17  827 
transcripts); and in basal-like tumors, 32% were dynami-
cally differentially expressed (18  505 transcripts). Further 
research is required to understand which of these changes 
are caused by disease progression, which may drive pro-
gression, which are not relevant to tumor progression, and 
how these changes at the transcriptional level are encoded in 
the proteome and functionally relevant. If such large-scale 
dynamic transcriptomic changes are confirmed in further 
experiments, it would require a rethinking of how we view 
breast cancer to understand it as a dynamic system con-
stantly responding to and changing its environment. Such 
a reconsideration of a tumor as a “static” disease is already 
occurring through thinking about how breast tumors relate 
to the immune system, to vascularization, and to the tumor 
microenvironment.33-35 Specifically, we believe that longi-
tudinal, RNA-seq studies of mice with xenograft tumors in 
individual mice is a natural next step to further investigate 
the findings presented in this work.
During our dynamic differential expression analysis, we were 
particularly interested to find that our inferred tumor progres-
sion RNA-seq profiles indicate that protein ADP-ribosylation 
activity may be decreasing as tumors progress in severity. 
Reduced ADP-ribosylation activity could be because advanced 
tumors have less of a need for ADP ribosylation. Based on this 
finding, we predict that the newly approved PARP inhibitors for 
breast cancer treatment will have a greater effect on early-stage 
breast cancer tumors than on late-stage tumors.2 Although, we 
note that PARP1 and PARP2 (the primary targets of PARP in-
hibitors) increased or remained stable throughout tumor pro-
gression, which may lead to a stable effect of PARP inhibitors 
across tumor stages. We therefore recond that further studies 
evaluate PARP inhibitor effectiveness across tumor stages.
In addition to investigating tumor progression using a 
continuous metric, we also predicted tumor growth rates 
from RNA-seq data. Previous studies estimating cancer cell 
growth and tumor volume doubling time have attributed the 
mismatch between maximal cancer growth rate, like that 
seen in vitro, and tumor volume doubling time, as seen in 
vivo, to lack of nutrient availability or increased cell death.25 
Our work, however, points to the fraction of cancer cells pro-
liferating in a tumor at a given time (or the mitotic index) as 
the important factor governing the difference between cel-
lular doubling times and tumor doubling times. Our growth 
rate predictor combines an RNA-based regression equation 
predicting growth rate in vitro with an estimator predicting 
mitotic index in vivo to quantitatively predict human cell 
doubling time in vitro and tumor doubling time in vivo quan-
titatively, which allowed us to compare our growth rate pre-
dictions to clinically observed tumor doubling times in breast 
cancer. This is in contrast to previous growth-related met-
rics, which are semi-quantitative.5-7 It is also important to 
recognize that our growth rate predictor is a fixed-parameter 
regression model, meaning that there are no free parameters 
or “wiggle room” to use for fitting data. Thus, the agreement 
between our predicted growth rates and clinically measured 
growth rates across breast cancer subtypes was not fitted but 
comes entirely from the theoretical derivation of our model.
In summary, the work presented in this study takes the 
first steps toward identifying the molecular events underlying 
the natural history of primary breast cancer and presents a 
model to estimate breast cancer growth rate completely from 
RNA-seq data. The methods presented in this work are gen-
eral and can be used to investigate progression and growth 
across a variety of cancer types. In breast cancer, although 
the combination of progression score and growth rate were 
largely uninformative for patient survival, this may not be the 
case for cancers that are considered to be “proliferation in-
formative,” such as Kidney Renal Clear Cell Carcinoma or 
Adenoid cystic carcinoma (ACC).23
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